Geron Corp SEC filings GERN
Geron Corp has 1,002 filings in SEC EDGAR's recent list, going back to Nov 16, 2009. Its latest annual report, Form ARS, was filed on Apr 7, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 7, 2026 | — |
| DEF 14A | Proxy statement | Apr 7, 2026 | May 20, 2026 |
| DEFA14A | Additional proxy material | Apr 8, 2025 | — |
| DEF 14A | Proxy statement | Apr 8, 2025 | May 21, 2025 |
| DEFA14A | Additional proxy material | Mar 27, 2024 | — |
| DEF 14A | Proxy statement | Mar 27, 2024 | May 9, 2024 |
| DEFA14A | Additional proxy material | Apr 14, 2023 | — |
| DEFA14A | Additional proxy material | Apr 12, 2023 | — |
| DEF 14A | Proxy statement | Apr 12, 2023 | — |
| PRE 14A | Preliminary proxy statement | Mar 31, 2023 | May 31, 2023 |
| DEFA14A | Additional proxy material | Mar 22, 2022 | — |
| DEF 14A | Proxy statement | Mar 22, 2022 | May 10, 2022 |
| DEFA14A | Additional proxy material | Mar 22, 2021 | — |
| DEF 14A | Proxy statement | Mar 22, 2021 | May 11, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 11, 2021 | May 11, 2021 |
| DEFA14A | Additional proxy material | Apr 14, 2020 | — |
| DEF 14A | Proxy statement | Apr 14, 2020 | Jun 5, 2020 |
| DEFA14A | Additional proxy material | Apr 22, 2019 | — |
| DEF 14A | Proxy statement | Apr 22, 2019 | Jun 6, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 8, 2019 | Jun 6, 2019 |
| DEFA14A | Additional proxy material | Mar 30, 2018 | — |
| DEF 14A | Proxy statement | Mar 30, 2018 | May 15, 2018 |
| DEFA14A | Additional proxy material | Mar 24, 2017 | — |
| DEF 14A | Proxy statement | Mar 24, 2017 | May 9, 2017 |
| DEFA14A | Additional proxy material | Apr 1, 2016 | — |
| DEF 14A | Proxy statement | Apr 1, 2016 | May 17, 2016 |
| DEFA14A | Additional proxy material | Apr 3, 2015 | — |
| DEF 14A | Proxy statement | Apr 3, 2015 | May 18, 2015 |
| DEFA14A | Additional proxy material | Apr 4, 2014 | — |
| DEF 14A | Proxy statement | Apr 4, 2014 | May 20, 2014 |
| DEFA14A | Additional proxy material | Apr 5, 2013 | — |
| DEF 14A | Proxy statement | Apr 5, 2013 | May 22, 2013 |
| DEFA14A | Additional proxy material | Apr 24, 2012 | — |
| DEFA14A | Additional proxy material | Apr 3, 2012 | — |
| DEF 14A | Proxy statement | Apr 3, 2012 | May 17, 2012 |
| PRE 14A | Preliminary proxy statement | Mar 23, 2012 | May 17, 2012 |
| DEFA14A | Additional proxy material | Mar 28, 2011 | — |
| DEF 14A | Proxy statement | Mar 28, 2011 | May 11, 2011 |
| DEFA14A | Additional proxy material | Mar 29, 2010 | — |
| DEF 14A | Proxy statement | Mar 29, 2010 | May 19, 2010 |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GERN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 886744
- Former names
- GERON CORPORATION (until Aug 5, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.